Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,963,572
  • Shares Outstanding, K 76,697
  • Annual Sales, $ 937,820 K
  • Annual Income, $ -626,600 K
  • 60-Month Beta 0.63
  • Price/Sales 3.28
  • Price/Cash Flow 16.56
  • Price/Book N/A
Trade PTCT with:

Options Overview Details

View History
  • Implied Volatility 54.62% ( -9.37%)
  • Historical Volatility 82.47%
  • IV Percentile 24%
  • IV Rank 26.30%
  • IV High 165.94% on 01/24/24
  • IV Low 14.90% on 09/08/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 6,842
  • Open Int (30-Day) 6,824

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.14
  • Number of Estimates 8
  • High Estimate -0.67
  • Low Estimate -1.63
  • Prior Year -2.66
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.00 +58.20%
on 04/25/24
40.69 -6.71%
on 05/21/24
+12.55 (+49.39%)
since 04/23/24
3-Month
24.00 +58.20%
on 04/25/24
40.69 -6.71%
on 05/21/24
+10.89 (+40.23%)
since 02/23/24
52-Week
17.53 +116.54%
on 11/02/23
48.63 -21.94%
on 05/24/23
-20.45 (-35.01%)
since 05/23/23

Most Recent Stories

More News
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 37.78 (-2.23%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 37.78 (-2.23%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 126.39 (-1.49%)
PTCT : 37.78 (-2.23%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 37.78 (-2.23%)
Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 37.78 (-2.23%)
RPRX : 26.95 (-1.39%)
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023...

PTCT : 37.78 (-2.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTCT : 37.78 (-2.23%)
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio...

PTCT : 37.78 (-2.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTCT : 37.78 (-2.23%)
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

PTCT : 37.78 (-2.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 41.18
2nd Resistance Point 40.10
1st Resistance Point 39.37
Last Price 37.78
1st Support Level 37.56
2nd Support Level 36.48
3rd Support Level 35.75

See More

52-Week High 48.63
Last Price 37.78
Fibonacci 61.8% 36.75
Fibonacci 50% 33.08
Fibonacci 38.2% 29.41
52-Week Low 17.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar